羅欣藥業(002793.SZ):擬放棄北京健康部分優先認繳出資權
格隆匯9月14日丨羅欣藥業(002793.SZ)公佈,公司控股子公司羅欣健康科技發展(北京)有限公司(“北京健康”)目前註冊資本為人民幣10000萬元,擬增加註冊資本人民幣12790萬元,公司擬以自有資金人民幣3290萬元的價格認購其中3290萬元的註冊資本,北京健康其他現有股東得怡成都擬以自有資金人民幣9500萬元的價格認購其中9500萬元的註冊資本。此次增資完成後,北京健康的註冊資本變更為人民幣22790萬元。
公司綜合考慮自身業務發展和戰略規劃,決定就此次增資放棄部分優先認繳出資權,放棄出資金額為人民幣6991.66萬元。此次增資完成後,公司對北京健康持股比例將由83.33%降至51.00%,仍為其控股股東並繼續將其納入合併報表範圍。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.